Diabetes
Refine Search
Pharmaceutical
The type 1 diabetes (T1D) market across the seven major markets (7MM: USA, France, Germany, Italy, Spain, the UK, and Japan) is set to grow at a compound annual growth rate (CAGR) of 13.3% from $2.2 billion in 2023 to $9.9 billion in 2033. 2 January 2025
Generics
Viatris has disclosed that its oral finished-dose manufacturing facility in Indore, India, is subject to regulatory action from the US regulator, after an inspection earlier this year. 24 December 2024
Generics
The US Food and Drug Administration (FDA) revealed on Monday that it has approved the first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter. 24 December 2024
Pharmaceutical
US pharma major Eli Lilly has recently announced a £279 million ($365.5 million) investment in the UK at the International Investment Summit in London. 19 December 2024
Pharmaceutical
The Egyptian Drug Authority has approved EVA Pharma's insulin glargine injection, marking a significant milestone in its collaboration with US pharma major Eli Lilly. 18 December 2024
Pharmaceutical
The European Commission has approved unconditionally, under the EU Merger Regulation, the proposed acquisition of contract development and manufacture organization (CDMO) Catalent (NYSE: MCTLT) by Denmark’s Novo Holdings. 7 December 2024
Biotechnology
Novavax has agreed to sell its manufacturing plant in the Czech Republic to Novo Nordisk for $200 million. 6 December 2024
Pharmaceutical
Novo Nordisk will reduce the US list prices of two insulin products, Tresiba (insulin degludec) and Fiasp (insulin aspart), by over 70% from 2026. 6 December 2024
Pharmaceutical
Eli Lilly has announced a $3 billion investment to expand its recently acquired manufacturing facility in Wisconsin, USA. 6 December 2024
Pharmaceutical
Danish diabetes and obesity giant Novo Nordisk has announced plans to invest 2.9 billion Danish kroner ($410 million) to establish a cutting-edge quality control laboratory in Hillerød, Denmark. 6 December 2024
Biotechnology
Dutch privately held Amarna Therapeutics, which specializes in transformative gene therapies, has entered into a strategic collaboration with Sweden-based NorthX Biologics, a leading biologics manufacturing partner. 4 December 2024
Pharmaceutical
The China-based subsidiary of French pharma major Sanofi revealed it has signed a memorandum of cooperation with Beijing Municipal Bureau of Economy and Information Technology and Beijing Economic and Technological Development Zone today to invest approximately 1 billion euros ($1.05 billion) to establish a new manufacturing base. 3 December 2024
Pharmaceutical
Hua Medicine has announced promising new clinical findings for its glucokinase activator dorzagliatin, presented at the China BioMed Innovation and Investment Conference. 2 December 2024
Pharmaceutical
Australia’s Department of Health and Aged Care has developed a new API (application programming interface) for the efficient distribution of the monthly Pharmaceutical Benefits Scheme (PBS) schedule data. 2 December 2024
Biotechnology
Privately-held UK firm Quell Therapeutics, which positions itself as a pioneer in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, has announced that AstraZeneca has selected a candidate to progress in the type 1 diabetes (T1D) Treg cell therapy program. 18 November 2024
Pharmaceutical
French pharma major Sanofi today announced an investment of 40 million euros ($42.4 million) in its Lyon Gerland bioproduction site, consolidating its role as a strategic platform dedicated to immunology. 15 November 2024
Pharmaceutical
Privately-held Montanan firm Microbion has announced promising findings from its Phase II study of pravibismane, a topical treatment aimed at addressing diabetic foot ulcer infections (DFI). 14 November 2024
Pharmaceutical
While sky high expectations for Eli Lilly’s tirzepatide have not yet been realized, more positive data add to a growing sense that the future could be as bright as imagined. 14 November 2024
Pharmaceutical
Germany’s Merck KGaA was trading 5% lower as Thursday’s trading day neared its end, after the company announced its third-quarter financial results and outlook for the rest of the year. 14 November 2024
Pharmaceutical
Anglo-Swedish drugmaker AstraZeneca beat analyst expectations with its third-quarter 2024 revenue and earnings figures. 12 November 2024
Pharmaceutical
Danish diabetes care giant Novo Nordisk has announced the headline results from the fourth Phase IIIa trial for semaglutide, SUSTAIN2. Semaglutide is a new GLP-1 analogue administered subcutaneously once weekly. 18 December 2015
Pharmaceutical
The US Food and Drug Administration is eliminating the Risk Evaluation and Mitigation Strategy (REMS) for rosiglitazone-containing type 2 diabetes medicines. 18 December 2015
Pharmaceutical
The US Food and Drug Administration has awarded full clearance of Eli Lilly and Boehringer Ingelheim’s insulin glargine injection Basaglar, it has been announced. 17 December 2015
Pharmaceutical
Multinational drugmakers may lose their positions Russian insulin market, due to forthcoming establishment of a state insulin monopoly on the basis of Rostec, a state corporation, which is headed by Sergey Chemezov, a Russian millionaire, who is reportedly close to the country’s President Vladimir Putin, reports The Pharma Letter’s local correspondent. 10 December 2015
Pharmaceutical
Danish multinational pharmaceutical company Novo Nordisk has submitted a new drug application (NDA) for faster-acting insulin aspart, it has been announced. 9 December 2015
Pharmaceutical
A US Food and Drug Administration safety review has resulted in adding warnings to the labels of a specific class of type 2 diabetes medicines called sodium-glucose cotransporter-2 (SGLT2) inhibitors about the risks of too much acid in the blood and of serious urinary tract infections. Both conditions can result in hospitalization. 7 December 2015
Pharmaceutical
In what is seen as a major blow to Eli Lilly’s diabetes program, the company said on Friday that it will cease development of basal insulin peglispro (BIL), a potential treatment for type 1 and type 2 diabetes. 6 December 2015
Pharmaceutical
Danish diabetes care giant Novo Nordisk today announced the submission to the European Medicines Agency of the Marketing Authorization Application (MAA) for the approval of faster-acting insulin aspart. 4 December 2015
Pharmaceutical
US drug major Eli Lilly said combination late-stage trials for its Trulicity (dulaglutide), to treat type 2 diabetes, has demonstrated it to be significantly effective versus treatment with sulfonylurea alone. 2 December 2015
Pharmaceutical
Danish insulin giant Novo Nordisk has said a new analysis showed Ryzodeg (insulin degludec/insulin aspart) achieved successful glycemic control with significantly lower rates of hypoglycemia and nocturnal hypoglycemia in patients with type 2 diabetes versus BIAsp 30 and/or a basal-bolus regimen of insulin degludec and insulin aspart. 2 December 2015
Pharmaceutical
Global healthcare company Novo Nordisk has presented the results of four diabetes studies at the World Diabetes Congress in Vancouver this week 1 December 2015
Biotechnology
US drug developer XOMA Corp has entered into a licensing deal with Danish diabetes care giant Novo Nordisk for a diabetes program. 1 December 2015
Pharmaceutical
Oramed Pharmaceuticals said it has signed definitive licensing and investment agreements worth up to $50 million with Hefei Tianhui Incubator of Technologies (HTIT) for exclusive rights to market Oramed's oral insulin capsule in China, Hong Kong and Macau. 1 December 2015
Generics
Jordon-based Hikma Pharmaceuticals has officially announced its plans for the building of a manufacturing plant in Almaty, the largest city of Kazakhstan during the next several years, reports The Pharma Letter’s local correspondent. 30 November 2015
Generics
Cheaper generic drugs may soon be commonplace in India with the government aiming to sell around 400 medications at lower prices by this December, through its Jan Aushadhi stores. 30 November 2015
Biosimilars
The type 1 diabetes mellitus (T1DM) market across the eight major countries of the USA, Canada, France, Germany, Italy, Spain, the UK and Japan will expand from $4.2 billion in 2014 to $7.1 billion by 2021, at a robust compound annual growth rate (CAGR) of 7.9%, new research indicates. 25 November 2015
article
Geropharm, one of Russia’s largest drugmakers, plans to build a new plant for the production insulin substance in Russia during the next several years, according to recent statements by Petr Rodionov, head of the company. 24 November 2015
Pharmaceutical
Indian drugmaker Zydus Cadila has launched its Tenglyn (teneligliptin 20mg) tablets, which belongs to a new class of oral anti-diabetic agents dubbed gliptins. 21 November 2015
Pharmaceutical
German life sciences company announced today that it plans to considerably expand its presence on the African continent over the next five years and is counting on the region’s entrepreneurial spirit and innovation power for growth. 20 November 2015
Pharmaceutical
The German Institute for Quality and Efficiency in Health Care (IQWiG), which last month had already found an added benefit of the drug for patients with advanced melanoma (The Pharma Letter October 20, now examined in another dossier assessment whether Bristol-Myers Squibb’s Opdivo (nivolumab) also offers an added benefit over the appropriate comparator therapy in the treatment of non-small cell lung cancer (NSCLC). 18 November 2015
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze